TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04047355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol is a beta-blocker used to treat high blood pressure, irregular heartbeats, and tremors. It is used after a heart attack and to prevent migraine headaches and chest pain. It is also used off-label for anxiety and PTSD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol
Description: Propranolol is a beta-blocker used to treat high blood pressure, irregular heartbeats, and tremors. It is used after a heart attack and to prevent migraine headaches and chest pain. It is also used off-label for anxiety and PTSD.
Study: NCT05784883

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: A comprehensive 2- and 3-dimensional transthoracic echocardiography (TTE) assessment of the tricuspid valve and right side of the heart at baseline.
Study: NCT06243640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buagafuran capsules, 15mg/ capsule
Description: Subjects took Buagafuran capsules; twice per day, respectively, after breakfast and dinner for 8 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buagafuran capsules, 15mg/ capsule
Description: Subjects took Buagafuran capsules; twice per day, respectively, after breakfast and dinner for 8 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buagafuran capsules mimic, 0mg/ capsule
Description: Subjects took Buagafuran capsules mimic. twice per day, respectively, after breakfast and dinner for 8 weeks;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buagafuran capsules mimic, 0mg/ capsule
Description: Subjects took Buagafuran capsules mimic. twice per day, respectively, after breakfast and dinner for 8 weeks;
Study: NCT05210387

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Duration of therapy
Description: In experimental group patients with severe infection caused by MDR-GNB and who present a clinical response on day 7 (±1) of adequate antimicrobial therapy, the therapy will be suspended.~The active control group will continue therapy until day 14 (±1).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration of therapy
Description: In experimental group patients with severe infection caused by MDR-GNB and who present a clinical response on day 7 (±1) of adequate antimicrobial therapy, the therapy will be suspended.~The active control group will continue therapy until day 14 (±1).
Study: NCT06452095

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Hyperbaric Oxygen therapy
Description: The SECHRIST INDUSTRIES Models 3600 and 4100 (H/HR) Hyperbaric Chambers are Monoplace Pressure Chambers designed to administer oxygen at near 100% concentration as the hyperbaric treatment gas, up to 3.0 atmospheres absolute (ATA) of pressure (29.4 psig). This study will utilize the 3600 and 4100 (H/HR) Hyperbaric Chambers located at Toronto General Hospital, Rouge Valley Hyperbaric Medicine Unit and Restore Hyperbaric Oxygen \& Medical Centre.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen therapy
Description: The SECHRIST INDUSTRIES Models 3600 and 4100 (H/HR) Hyperbaric Chambers are Monoplace Pressure Chambers designed to administer oxygen at near 100% concentration as the hyperbaric treatment gas, up to 3.0 atmospheres absolute (ATA) of pressure (29.4 psig). This study will utilize the 3600 and 4100 (H/HR) Hyperbaric Chambers located at Toronto General Hospital, Rouge Valley Hyperbaric Medicine Unit and Restore Hyperbaric Oxygen \& Medical Centre.
Study: NCT03827031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mutlidisciplinary medication Review (MMR)
Description: The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mutlidisciplinary medication Review (MMR)
Description: The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up
Description: Multidisciplinary medication review (MMR) The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community physician to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient.~Community follow-up A summary of the follow-up report stating the therapeutic modifications (called below multidisciplinary correspondence documents) will be sent to the community pharmacist and physician. Within 2 months of discharge, the pharmacist performs a follow-up of medication changes accepted and not accepted by the community physician.~Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted.
Study: NCT06650462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-led discussion
Description: Participants engage in weekly community-led small group discussions about health related topics
Study: NCT05597930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist and Thumb orthosis
Description: Custom 3D printed thumb and wrist orthosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist and Thumb orthosis
Description: Custom 3D printed thumb and wrist orthosis
Study: NCT05250739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Strength training was performed with resistance bands. The band was fastened to the unaffected ankle, while the participant was told to perform front and back pulls, as well as adduction and abduction movements with the affected ankle. They were told to control the ankle movement and to make it slow. Since the first day, they were told to perform the exercise pulling the band as if they wanted to make the resistance of 5 on a scale from 0 to 10.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular training
Description: consisted in a multi-station training with 6 exercises, increasing the difficulty progressively as the participants controlled the execution. The exercises were all performed barefoot and with the injured foot. These were a combination of standing and jumping exercises involving the injured ankle. The participants did not start the next progression until they perform a complete circuit in the level before.
Study: NCT04366115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVM0703
Description: Single IV infusion at 10 mg/mL in normal saline over 1 hour to patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVM0703
Description: Single IV infusion at 10 mg/mL in normal saline over 1 hour to patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV infusion in normal saline over 1 hour to patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV infusion in normal saline over 1 hour to patients.
Study: NCT04936737

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine supplementation
Description: The supplementation will be administrated in the dosage of 20mg.kg-1. On the first and the sixth (last one), one dose of beta-alanine will be taken. On the other four days of supplementation, the volunteers will take 2 doses (20mg.kg-1) of Beta-alanine.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine supplementation
Description: The supplementation will be administrated in the dosage of 20mg.kg-1. On the first and the sixth (last one), one dose of beta-alanine will be taken. On the other four days of supplementation, the volunteers will take 2 doses (20mg.kg-1) of Beta-alanine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval exercise
Description: The HIIE sessions will consist of 10 series of 1 min of effort, divided into two blocks of 5 series each. There will be an interval of 5 min of passive recovery; within each block, the interval between sets will be 1 min of active recovery. The exercise will be conducted in a mechanical brake cycle ergometer, with load applied by placing washers on a load plate (Biotec 2100, Cefise, Brazil).
Study: NCT05152498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fu Zheng Jie Du Hua Yu therapy
Description: Fu Zheng Jie Du Hua Yu is a Chinese herbal compound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fu Zheng Jie Du Hua Yu therapy
Description: Fu Zheng Jie Du Hua Yu is a Chinese herbal compound
Study: NCT06503666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ZAIMARA
Description: The ZAIMARA curriculum focuses on strengthening communication between adolescent girls and young women (AGYW) and their mother figures (MF) to make healthy sexual decisions, to learn more about HIV, sexually transmitted infections (STIs), and pre-exposure prophylaxis (PrEP). The topics in the curriculum focus on effective communication, mothers talking to daughters on sex, HIV, STIs and PrEP. The intervention consists of participants attending a two day workshops with their MF.~Other names:~ZAIMARA

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Promotion
Description: The health promotion (HP) curriculum focuses on healthy living by encouraging good nutrition, improving knowledge on violence recognition, management and support/resources, exercise, informed consumer behavior, alcohol and substance use.The intervention consists of participants attending a two day workshops with their MF.~Other names:~HP
Study: NCT06337695

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: 300 mg IV at weeks 0, 3, 6, 14, and 22

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300 mg IV at weeks 0, 3, 6, 14, and 22
Study: NCT04627363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg intravenously every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg intravenously every 3 weeks
Study: NCT05706571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group (skill laboratory), experimental group 1 (Banner model) and experimental group2 (augmented reality mobile application)
Description: In the research, the control group will form the control group of both experiment one and experiment two. In the creation of quantitative and qualitative data, it will be formed in three groups, two of which are the experimental group and one is the control group. While forming the experimental and control groups of the research, it is planned to ensure homogeneity between the groups by making random and unbiased selection. It is planned to do a pre-test before applying the child patient end-of-life care module of nursing students of teaching with augmented reality and Benner model to the experimental and control groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group (skill laboratory), experimental group 1 (Banner model) and experimental group2 (augmented reality mobile application)
Description: In the research, the control group will form the control group of both experiment one and experiment two. In the creation of quantitative and qualitative data, it will be formed in three groups, two of which are the experimental group and one is the control group. While forming the experimental and control groups of the research, it is planned to ensure homogeneity between the groups by making random and unbiased selection. It is planned to do a pre-test before applying the child patient end-of-life care module of nursing students of teaching with augmented reality and Benner model to the experimental and control groups.
Study: NCT06447415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7450
Description: HRS-7450 Injection
Study: NCT05105100

Intervention type: PROCEDURE
Intervention: Biopsy
Description: Tumor tissue collection

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Intravenously Blood draw
Study: NCT06447415

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride injection
Description: 0.9% sodium chloride injection
Study: NCT05863871

Intervention type: DRUG
Intervention: Linperlisib
Description: 80 mg, qd
Study: NCT05072795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Task (TSST)
Description: The TSST is a standardized psychological stress challenge which provokes a stress response in a laboratory setting. During the task, saliva samples will be collected for hormone testing along with physiological and subjective measures.
Study: NCT04722627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-752
Description: Parallel Assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-752
Description: Parallel Assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-752
Description: Parallel Assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-752
Description: Parallel Assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-752
Description: Parallel Assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-752
Description: Parallel Assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-752
Description: Parallel Assignment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Parallel Assignment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Parallel Assignment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Parallel Assignment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Parallel Assignment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Parallel Assignment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Parallel Assignment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Parallel Assignment
Study: NCT03958929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: The film follows the journey of an elderly patient scheduled to undergo glaucoma surgery, beginning with a face-to-face Q\&A health session with an eye doctor. After surgery, the patient talks about his post-operative eyesight and discusses the benefits of early diagnosis and glaucoma surgery for treatment with his community.
Study: NCT06511843

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Coping Information
Description: A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lyrical Music
Description: A 4-minute audio recording of Leonard Cohen's song Hallelujah sung by Rufus Wainwright with choral accompaniment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instrumental Music
Description: A 4-minute audio recording of instrumental, theta wave music.
Study: NCT05876806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib is a 150 mg twice daily capsule administered orally on a continuous basis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib is a 2 mg once daily tablet administered orally on a continuous basis.
Study: NCT05027867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: Administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: Administered by mouth
Study: NCT03833024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized Purified Flavonoid Fraction
Description: After randomization (1:1 with stratification by centre) patients will receive 1000 mg of oral MPFF (Venixxa, one 500mg tablet BID) for 6 months, in addition to their usual PTS and DVT treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After randomization (1:1 with stratification by centre) patients will receive an oral placebo (one tablet BID) for 6 months, in addition to their usual PTS and DVT treatment
Study: NCT05349357

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sliding Neural mobilization
Description: Sliding neural mobilization to femoral, sciatic and tibial nerve

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tensioner Neural mobilization
Description: Tensioner neural mobilization to femoral, sciatic and tibial nerve

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercises
Description: Stretching exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercises
Description: Stretching exercises

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS
Study: NCT05733442

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU entails medication to support patients' recovery (i.e., the partial opioid agonist, buprenorophine + naloxone/ Suboxone gel films), in-person case management and behavioral health intervention (i.e., in-person group and individual counseling), and referrals to other health care and behavioral health services.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHaRRM-CN
Description: The CHaRRM-CN intervention includes changes and additions to TAU to make MAT more culturally aligned (i.e., offering regular community-based, cultural programming; offering culturally aligned healing groups in the MAT program, such as Talking Circles and beading group) as well as lower barrier and incentivized (i.e., offering medication and behavioral health appointments via in-person, videoconference or telephone; offering harm-reduction groups in addition to abstinence-based groups; providing mailed and in-person pick-up options for buprenorphine prescriptions; conducting weekly chart reviews to ensure prescriptions and basic needs are continuously met; bimonthly, automated text outreach; contingency management supporting attendance at in-person or telehealth appointments).
Study: NCT04990934

Intervention type: BEHAVIORAL
Intervention: Semistructured Interview
Description: Patients with breast cancer (Stage I-III) will be interviewed about their experiences of telemedicine.

Intervention type: BEHAVIORAL
Intervention: Semistructured Interview
Description: Patients with breast cancer (Stage I-III) will be interviewed about their experiences of telemedicine.
Study: NCT06137456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeletal robotic therapy for walking.
Description: Exoskeletal robotic therapy for walking. Therapy sessions were scheduled for 40 minutes each. The study group performed exoskeleton walking and balance exercises 3 days a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise therapy
Description: Conventional treatment consisted of walking and balance exercises, stretching, strengthening, and mobility exercises, for 40 minutes, 5 days a week.
Study: NCT05828017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid - Standard Curve
Description: Our current hearing aids which will be programmed to our standard frequency response curve.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid - Variation #1
Description: Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
Study: NCT05668065

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoronaVac/CoronaVac
Description: Two doses at 21-day +/- 3 days. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac/BNT162b2
Description: First dose of Coronavac. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.~Second dose of BNT162b2 at 21-day +/- 3 days. Each dose of the Pfizer-BioNTech COVID-19 Vaccine is 0.3 ml. Each prefilled syringe contains 30 mcg of a nucleoside-modified messenger RNA (modRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2
Study: NCT06142799

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: root canal treatment
Description: The root canal completedwill be completed. Then randomly it will be decided if the planned and milled overlay is placed the same day or delayed one week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root canal treatment
Description: The root canal completedwill be completed. Then randomly it will be decided if the planned and milled overlay is placed the same day or delayed one week